More new drugs; more new trials


Two small companies have today announced initial clinical trials of two new investigational agents for the treatment of prostate cancer.

Bostwick Therapeutics (a division of Bostwick Laboratories) has just announced that it has received clearance to initiate the CRITICAL (CRyotherapy and IntraTumoral Immunotherapy with immature dendritic Cells (AutoLogous)) trial, a clinical trial examining the potential of a novel combination of cryoablation and intra-tumoral injection of “virgin” dendritic cells (VDC2008) to treat men with metastatic androgen-independent prostate cancer.

In addition, Progenics Pharmaceuticals has announced the initiation of a phase I dose-escalation clinical study of its prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC). PSMA ADC is an investigational therapy that combines a prostate-cancer antibody with a derivative of a cancer drug known as auristatin.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: